Stroke prevention is the cornerstone of manage ment in patients with atrial fibrillation (AF). Contemporary international clinical guidelines advocate oral anticoagulation (OAC) therapy for patients with AF with ≥1 risk factors for stroke, and aspirin monotherapy is no longer recommended. However, a time-lag is often observed in the translation of guideline recommendations into clinical practice, and guideline-adherent treatment is frequently less than optimal. Two large cohort studies now report disparities between guideline recommendations for OAC therapy and prescribing patterns in clinical practice 1, 2 .
In 2016, an analysis of the ACC PINNACLE registry 1 found that among a cohort of 294,642 patients at high risk of stroke (CHADS 2 or CHA 2 DS 2 -VASc score ≥2), 40% of patients were prescribed aspirin monotherapy, with significant variation in OAC prescription across practices. According to multivariable analyses, guideline-adherent OAC treatment was more likely among men, and among those with higher BMI, and previous thromboembo lism and congestive heart failure (FIG. 1) . Those receiving aspirin were more likely to have comorbidities associated with coronary athero sclerosis 1 . Furthermore, an examination of trends in OAC prescription and degree of guideline-adherent OAC prescription in patients with incident AF from 2001-2011 from the Veterans Health Administration 2 revealed that less than half (47%) received monotherapy 1, 3, 4 , particularly the elderly (aged ≥75 years), and many low-risk patients were inappropriately prescribed OAC therapy [2] [3] [4] . This phenomenon is particularly worrying given that appropriate OAC treatment in at-risk patients with AF could help to prevent avoidable strokes and deaths, whereas inappro priate OAC prescription (among those with no risk factors) places patients at risk of major bleeding. Although the data from these two large studies are generally consistent with earlier large-scale registries 3, 4 , a more recent study from the USA suggests greater adherence to OAC guideline recommendations and a more than threefold increase in the uptake of the NOACs Although both studies are based on large USA cohorts -one a prospective cohort 1 and the other a retrospective health-care claims database 2 -prescription of antithrombotic therapy might vary considerably by geographical location. In addition, centres providing data to the PINNACLE registry were all special ized cardiology practices and, therefore, prescription of OAC might be higher than in general AF populations managed outside of cardiology practices. In addition, antithrombotic therapy was based on prescription at baseline and treatment might have changed over time 1 . Patients from the Veterans Health Administration might have received their treatment from outside this system, resulting in noncapture of some OAC prescriptions that might account for the lower OAC prescription rates to suboptimal OAC use in this population. Studies published in the past year demonstrated that patients with a single risk factor for stroke not related to sex (that is, CHA 2 DS 2 -VASc score = 1 in men and CHA 2 DS 2 -VASc score = 2 in women) would benefit from OAC, whereas aspirin had a negative net clinical bene fit 6, 7 . Of note, reported event rates varied with different cohorts and study setting (for example, hospitalized versus community-based), and appropriate study methodology 8 .
The reasons for not prescribing OAC therapy in eligible patients are multifactorial, but can be distilled down to physician choice and patient refusal. A very small proportion for whom OAC therapy is absolutely contraindicated exists, but these patients should not be prescribed aspirin as alternative therapy. Physicians often fear a greater risk of bleeding associated with OAC treatment and, therefore, patients might never be offered the option of OAC therapy. By contrast, evidence suggests that aspirin is minimally effective for stroke prevention in patients with AF 9 , and has a similar risk of major bleeding to that with OAC treatment, with a significant reduction in intracranial haemorrhage with NOACs (compared with warfarin). Patients often have different perceptions about OAC therapy, which might influence their treatment choices; they are eager to reduce their risk of stroke and are consequently more willing to accept higher risk of bleeding 10 . In this context, patient and prescriber education are critical to enable understanding of the link between AF and increased risk of stroke, and the benefit of OAC therapy in addition to the associated bleeding risks, to allow patients to make an informed choice about treatment. Patient decision-making aids are available to assist health-care professionals in their discussions with patients about the advantages and disadvantages of OAC therapy in relation to individual stroke and bleeding risk.
Future research should focus on identifying the reasons for the inconsistency between guideline recommendations for OAC and real-life clinical practice, and implementing strategies to address this inconsistency. Examples of such strategies include physician and patient education programmes and an analysis of the effect of such programmes, equitable access to OAC therapy and services globally, and incentivized prescribing where necessary. We can certainly do much more to reduce the risk of stroke (and death) among patients with AF.
